Table 1.
Sample Demographic Characteristics
| Characteristic | CTx+ (n = 16) |
CTx− (n = 12) |
Control (n = 15) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| No. | Mean | SD | No. | Mean | SD | No. | Mean | SD | |
| Age at baseline, years | 52.9 | 8.6 | 52.7 | 7.2 | 50.5 | 6.0 | |||
| Years of education | 15.2 | 2.6 | 16.1 | 2.3 | 15.9 | 2.0 | |||
| Estimated full-scale IQ (Barona Index34) | 111.9 | 6.9 | 114.7 | 4.7 | 114.1 | 3.6 | |||
| Handedness | |||||||||
| Right | 14 | 12 | 13 | ||||||
| Left or ambidextrous | 2 | 0 | 2 | ||||||
| Days from baseline to M1 scan | 171.6 | 65.9 | 191.8 | 72.6 | 191.7 | 46.7 | |||
| Days from M1 to Y1 scan | 352.7 | 52.5 | 303.9 | 70.2 | 320.4 | 81.2 | |||
| Days from baseline to Y1 scan | 524.3 | 54.5 | 495.8 | 53.1 | 512.1 | 78.6 | |||
| Cancer stage | |||||||||
| 0 (DCIS)* | 0 | 4 | |||||||
| I | 4 | 6 | |||||||
| II | 11 | 2 | |||||||
| IIIA | 1 | 0 | |||||||
| Received radiotherapy | 11 | 10† | |||||||
| No. receiving antiestrogen therapy‡ | |||||||||
| Baseline | 0 | 1 TAM | |||||||
| M1 | 3 TAM | 6 TAM | |||||||
| 1 ANA | 1 TAM/ GOS | ||||||||
| 2 ANA | |||||||||
| Y1 | 9 TAM | 6 TAM | |||||||
| 1 ANA | 1 TAM/ GOS | ||||||||
| 2 LET | 2 ANA | ||||||||
| No. receiving psychotropic medication | |||||||||
| Baseline | 4 | 5 | |||||||
| M1 | 5 | 4 | |||||||
| Y1 | 5 | 6 | |||||||
| Chemotherapy regimen§ | |||||||||
| Doxorubicin/cyclophosphamide/paclitaxel | 11 | ||||||||
| Docetaxel/doxorubicin/cyclophosphamide | 2 | ||||||||
| Doxorubicin/cyclophosphamide | 3 | ||||||||
| Menstrual status∥ | |||||||||
| Menstruating throughout study | 0 | 4 | 7 | ||||||
| Postmenopausal (> 6 months) throughout study | 9 | 5 | 6 | ||||||
| Periods irregular at study entry, entered menopause (> 6 months) during study | 2 | 2 | 2 | ||||||
| Periods regular at study entry, entered menopause (> 6 months) during study | 4 | 1 | 0 | ||||||
Abbreviations: ANA, anastrozole; CTx+, patients treated with chemotherapy; CTx−, patients not treated with chemotherapy; DCIS, ductal carcinoma in situ; GOS, goserelin; IQ, intelligence quotient; LET, letrozole; M1, 1 month after completion of chemotherapy; SD, standard deviation; TAM, tamoxifen; Y1, 1 year after M1 visit.
*
Significant between-group difference, P = .01.
†
Eight received conventional local radiation; two received MammoSite baseline scans (3 and 36 days before scanning, respectively).
‡
One CTx− participant began TAM 18 days before her baseline scan.
§
One CTx+ patient was treated with trastuzumab for 2 months after completion of chemotherapy.
∥
Menstrual status was unknown for one CTx+ patient.